Driven by steady demand for Darzalex in the US, Europe and Japan, total revenue surged by 51.8% in Q2 19. Growth in operating expenses was even higher (+70%), due to higher investments into R&D and, as a consequence, operating income was largely flat vs. Q2 18. Given that the Darzalex-Revlimid combo is now approved in the US in the frontline MM indication, the upgraded FY19 guidance seems within reach.
21 Aug 2019
Decent results; full-year guidance raised slightly
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Decent results; full-year guidance raised slightly
Genmab A/S (GMAB:WBO) | 0 0 1.3% | Mkt Cap: 66,508m
- Published:
21 Aug 2019 -
Author:
Sumit Sayal -
Pages:
3
Driven by steady demand for Darzalex in the US, Europe and Japan, total revenue surged by 51.8% in Q2 19. Growth in operating expenses was even higher (+70%), due to higher investments into R&D and, as a consequence, operating income was largely flat vs. Q2 18. Given that the Darzalex-Revlimid combo is now approved in the US in the frontline MM indication, the upgraded FY19 guidance seems within reach.